NCD Program Database
The objective of this program is to enable Malaysian patients with relapased and refractory Hodgkin’s lymphoma (RR HL) or relapsed and refractory systemic anaplastic large cell lymphoma (RR sALCL) to complete their entire course of treatment with Adcetris®, even if they cannot afford to pay for it in full, and ultimately to reduce the burden of the disease in Malaysia in terms of its impact on quality of life and mortality.
Before the launch of Adcetris® there were no treatment options for Malaysian patients with RR HL or RR sALCL.Takeda’s Patient Assistance Programs (PAPs) use an innovative, affordability-based approach to improve access to our specialty medicines in a sustainable way. They focus on patients living in areas where there exists high, unmet medical needs and where Takeda has sufficient presence so that we can achieve the greatest possible health impact. Patients are referred to the PAP by their prescribing physician. The patient and physician complete, sign and submit a single application form. Once the application is submitted, patients undergo a confidential means-based assessment using a validated tool designed and administered by an independent third party organization. The results of the assessment are used to develop a payment plan that details how many vials of treatment the patient will need to buy and how many will be covered by Takeda and other parties to complete the patient’s full treatment cycle. Patients enrolled in the program receive ongoing follow-up from the third party organization to ensure they are adhering to their treatment plan and to their physician’s recommendations.
The program's ultimate goal is to optimize care and treatment benefits, and reduce the burden of RR HL and RR sALCL in Malaysia in terms of its impact on quality of life and mortality in a way that is sustainable over the long term.